← FDA DRUG APPROVALS

FDA ANDA · ANDA061901

KANTREX

Sponsor: APOTHECON

APPLICATION
ANDA061901
TYPE
ANDA
ORIGINAL APPROVAL
1975-03-06
LATEST ACTION
2001-09-17
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

KANTREXDiscontinued
KANAMYCIN SULFATE EQ 75MG BASE/2ML · INJECTABLE · INJECTION
KANTREXDiscontinued
KANAMYCIN SULFATE EQ 500MG BASE/2ML · INJECTABLE · INJECTION
KANTREXDiscontinued
KANAMYCIN SULFATE EQ 1GM BASE/3ML · INJECTABLE · INJECTION

Approval history

2001-09-17Manufacturing (CMC) · Supplement 21AP
1998-09-02Manufacturing (CMC) · Supplement 20AP
1990-11-29Manufacturing (CMC) · Supplement 19AP
1975-03-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →